Skip to content

Prospective Evaluation of Topical Almond Oil vs Hydroquinone

Prospective Evaluation of Topical Almond Oil vs Hydroquinone on the Appearance of Facial Pigmentation and the Stability of the Microbiome

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04875715
Enrollment
50
Registered
2021-05-06
Start date
2021-07-01
Completion date
2026-08-01
Last updated
2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Pigmentation

Brief summary

The purpose of this study is to analyze facial pigmentation and skin microbiome changes after topical almond oil application, compared to the use of topical hydroquinone.

Detailed description

The purpose of this experiment is to analyze facial pigmentation and skin microbiome changes after topical almond oil application, compared to the use of topical hydroquinone. There will be a total of 50 subjects: * 25 randomized to receive almond oil nightly * 25 randomized to receive 2% hydroquinone nightly Study Timelines: * The duration of an individual subject's participation will last from the day of the consent/screening (visit 1) until visit 5 where they will have images taken and measurements collected to assess skin pigment, skin hydration, sebum excretion rate. * The duration of participation is 4 months. * The estimated time for the investigators to complete primary analysis is 2 years.

Interventions

Almond oil

DRUGHydroquinone Topical

Hydroquinone 2% cream

Sponsors

University of California, Davis
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Premenopausal women of Fitzpatrick skin types 3 to 6

Exclusion criteria

* Those with a nut allergy * Smoking is an independent risk factor and serves as a confounder for the development of facial aging \[18\]. Therefore current smokers, those that have smoked within the past year, and former smokers with greater than a 20 pack year history of smoking will be excluded. * Those with an autoimmune photosensitive condition or a known genetic condition with a deficiency in collagen production (such as Ehlers-Danlos syndrome) will be excluded as this can be a confounder for facial photoaging. * Hormonal medications or therapies will not be allowed unless they have been stable on their medications for at least 2 months. Examples include oral contraceptives, progesterone-based injections, and estrogen based hormonal replacement therapy. * Those who have undergone any cosmetic procedures to the face in the 4 months prior to enrollment in the opinion of the investigator. People that have undergone deeper chemical peels (TCA based peels) within 1 year prior to enrollment will also not be eligible. * Individuals who are unwilling to discontinue vitamin E containing supplements and food sources during the washout and intervention. * Individual who are unwilling to discontinue topical cosmetic products during the duration of the study. * Individuals who are not willing to engage in a two-week washout on topical treatments known to affect facial pigmentation and these agents will be restricted during the study period as well. These include topicals that contain: * Retinoids such as tretinoin, adapalene, retinol. * Antioxidant ingredients such as vitamin C or vitamin E. * Pigment-reducing agents such as hydroquinone, azelaic acid, kojic acid per the discretion of the investigator except for the hydroquinone that is provided in this study. * Topicals that contain a nut oil or nut extract as part of their ingredient list. * Furthermore, subjects will be asked to refrain from use of any other topical products for one week prior to each visit apart from the study agents supplied from this study.

Design outcomes

Primary

MeasureTime frameDescription
Intensity of facial pigment16 weeksFacial images will be obtained and analyzed with the BTBP image analysis system

Secondary

MeasureTime frameDescription
Shifts in the microbiome diversity (Shannon index as an example)16 weeksThe skin microbiome will be analyzed to assess any changes after topical almond oil application, compared to the use of topical hydroquinone.
Quantification for the presence of species within the genus Cutibacteria, Staphyloccoccus, and Ralstonia16 weeksThe skin microbiome will be analyzed to assess the presence of species within the genus Cutibacteria, Staphyloccoccus, and Ralstonia
Appearance of facial redness16 weeksThe research team will quantify the presence of facial redness with a SkinColorCatch from Delfin Technologies. This will measure the RGB colors and average them from each participant for each of the visits. Skin pigment, including the presence of redness, will be measured using a SkinColorCatch from Delfin Technologies. This device shows the RGB Colors, CIE L\*a\*b\* and L\*c\*h\* color space coordinates when the device is applied to the skin.Included is the link to the device (http://www.truesystem.co.kr/product/pdf/SkinColorCatch%20Brochure%202016.pdf).
Subjective tolerability assessment16 weeksA questionnaire that assesses for stinging, itching, and burning will be utilized.
Intensity of facial pigment8 weeksFacial images will be obtained and analyzed with the BTBP image analysis system

Countries

United States

Contacts

Primary ContactIryna Rybak
irybak@ucdavis.edu916-551-2636
Backup ContactAlexis Carrington
aecarrington@ucdavis.edu

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026